A new definition of obesity could nearly double the prevalence of U.S. adults with the condition, a new study published ...

Wegovy pill, the first ever non-injectable GLP-1 for obesity, from drugmaker Novo Nordisk. Competitors like Eli Lilly are ...

Over 27 percent of adults worldwide with obesity qualify for GLP-1 weight loss medicines but access remains unequal.

"Food noise" is the buzz in the battle against obesity. GLP1 injectables don't just decrease appetite, but also quiet "food ...

India faces a potential obesity crisis by 2050, with experts urging mindful eating and regular exercise to combat rising rates, especially in certain states.

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated ...

The consumer champion is now calling on the government to introduce a mandatory front-of-pack nutrition labelling scheme. It ...

Obesity is a complex, chronic condition that affects millions of Americans, and treating it often requires more than just ...